| 
           Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines.
            The web pages are not kept up to date and are for demonstration purposes only. 
            For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine. 
         | 
        BACK TO LIST | 
                     
  | 
                  
                     
 
  | 
                  
                     
 
  | 
               |||||||||||||||||||||||||
| Test | 28-DEC-2020 | Reference Range | Unit | 
|---|---|---|---|
| Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | 4.5 - 6.4 | % | 
| Glucose [Mass/volume] in Blood | 130.5 | 70 - 140 | mg/dL | 
| Urea nitrogen [Mass/volume] in Blood | 8.8 | 7 - 25 | mg/dL | 
| Creatinine [Mass/volume] in Blood | 0.7 | 0.6 - 1.3 | mg/dL | 
| Calcium [Mass/volume] in Blood | 9.1 | 8.5 - 10.5 | mg/dL | 
| Sodium [Moles/volume] in Blood | 143.5 | 135 - 145 | mmol/L | 
| Potassium [Moles/volume] in Blood | 4.3 | 3.5 - 5.1 | mmol/L | 
| Chloride [Moles/volume] in Blood | 103.4 | 98 - 107 | mmol/L | 
| Carbon dioxide, total [Moles/volume] in Blood | 24.9 | 22 - 29 | mmol/L | 
| Cholesterol [Mass/volume] in Serum or Plasma | 247.0 H | 0 - 200 | mg/dL | 
| Triglyceride [Mass/volume] in Serum or Plasma | 497.6 H | 0 - 199 | mg/dL | 
| Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay | 120.1 | 0 - 130 | mg/dL | 
| Cholesterol in HDL [Mass/volume] in Serum or Plasma | 27.4 L | 40 - 100 | mg/dL | 
| Microalbumin/Creatinine [Mass Ratio] in Urine | 14.7 | 0 - 30 | mg/g | 
| Conclusion and Recommendations based on this report and previous findings known to us | 
|---|
| The patient"s renal function, glucose metabolism, and electrolytes are within normal limits. However, there is significant dyslipidemia with elevated total cholesterol and triglycerides, low HDL, and borderline LDL, increasing cardiovascular risk. HbA1c is in the non-diabetic range. Recommend clinical follow-up for lipid management and cardiovascular risk reduction. |